Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
On March 28, 2025, FDA approved the use of Pluvicto® before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC )patients who have previously been treated with androgen receptor pathway inhibitor
The global radiopharmaceutical market is a large and rapidly growing industry, driven by advancements in radiodiagnostics, radiotherapeutics and population demand. The advances in radiodiagnostics is helping detect diseases like cancer in
Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
On March 28, 2025, FDA approved the use of Pluvicto® before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC )patients who have previously been treated with androgen receptor pathway inhibitor
The global radiopharmaceutical market is a large and rapidly growing industry, driven by advancements in radiodiagnostics, radiotherapeutics and population demand. The advances in radiodiagnostics is helping detect diseases like cancer in
“Supply Chain Logistics For A PET Radiotracer Manufacture”
Supply chain for an 18F radioisotope based PET radiotracer manufacture is discussed in detail along with brief manufacturing descriptions provided for context. A critical report for supply chain, manufacturing, business and investing personnel to familiarize with the basics of supply chain for this category of high application, commercially critical PET diagnostic imaging agents.
Click the icon below to download the eReport.
